Theralase(R) Extends Warrants
Theralase Technologies, a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated molecules for cancer and pathogen treatment, announced plans to extend the expiry date of 1,000,000 share purchase warrants. The warrants, originally issued on November 17, 2022, through a private placement, will be extended from November 17, 2024, to November 17, 2027. The warrants remain exercisable at $0.35 per share, with all other terms unchanged. The extension requires TSX Venture Exchange approval.
Theralase Technologies, un'azienda farmaceutica in fase clinica focalizzata su molecole attivate da luce, radiazione, suono e farmaci per il trattamento di cancro e patogeni, ha annunciato piani per estendere la data di scadenza di 1.000.000 di warrant per l'acquisto di azioni. I warrant, originariamente emessi il 17 novembre 2022 tramite un collocamento privato, saranno prolungati dal 17 novembre 2024 al 17 novembre 2027. I warrant rimangono esercitabili a $0,35 per azione, con tutte le altre condizioni invariate. L'estensione richiede l'approvazione del TSX Venture Exchange.
Theralase Technologies, una empresa farmacéutica en etapa clínica centrada en moléculas activadas por luz, radiación, sonido y medicamentos para el tratamiento del cáncer y patógenos, anunció planes para extender la fecha de vencimiento de 1.000.000 de garantías de compra de acciones. Las garantías, emitidas originalmente el 17 de noviembre de 2022 a través de una colocación privada, se extenderán del 17 de noviembre de 2024 al 17 de noviembre de 2027. Las garantías siguen siendo ejercitables a $0.35 por acción, con todos los demás términos sin cambio. La extensión requiere la aprobación de TSX Venture Exchange.
Theralase Technologies는 암 및 병원체 치료를 위한 빛, 방사선, 소리 및 약물 활성화 분자에 집중하는 임상 단계 제약 회사로, 1,000,000 주식 매입 증권의 만료일을 연장할 계획을 발표했습니다. 이 증권은 2022년 11월 17일에 사모 배정을 통해 처음 발행되었으며, 2024년 11월 17일에서 2027년 11월 17일로 연장됩니다. 증권은 $0.35 per share로 행사 가능하며, 다른 조건은 모두 동일합니다. 이 연장은 TSX 벤처 거래소의 승인이 필요합니다.
Theralase Technologies, une entreprise pharmaceutique en phase clinique axée sur les molécules activées par la lumière, les radiations, le son et les médicaments pour le traitement du cancer et des agents pathogènes, a annoncé des projets pour prolonger la date d'expiration de 1.000.000 de bons de souscription d'actions. Les bons, initialement émis le 17 novembre 2022 lors d'un placement privé, seront prolongés du 17 novembre 2024 au 17 novembre 2027. Les bons restent exerçables à $0,35 par action, toutes les autres conditions restant inchangées. Le prolongement nécessite l'approbation de la TSX Venture Exchange.
Theralase Technologies, ein pharmazeutisches Unternehmen in klinischer Phase, das sich auf licht-, strahlungs-, schall- und medikamentaktivierte Moleküle zur Behandlung von Krebs und Pathogenen konzentriert, hat Pläne angekündigt, das Ablaufdatum von 1.000.000 Aktienkaufsrechten zu verlängern. Die Rechte, die ursprünglich am 17. November 2022 im Rahmen einer Privatplatzierung ausgegeben wurden, werden vom 17. November 2024 auf den 17. November 2027 verlängert. Die Rechte bleiben zu $0,35 pro Aktie ausübbar, wobei alle anderen Bedingungen unverändert bleiben. Die Verlängerung bedarf der Genehmigung der TSX Venture Exchange.
- None.
- None.
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,000,000 share purchase warrants ("Warrants") from November 17, 2024 to November 17, 2027.
The Warrants were issued on November 17, 2022, pursuant to a private placement involving the issuance of 1,000,000 units of the Company. The Warrants are exercisable at
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's small molecules and their drug formulations, preclinical research, clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all, the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
Kristina Hachey, CPA
Chief Financial Officer
X 224
khachey@theralase.com
SOURCE: Theralase Technologies, Inc.
View the original press release on accesswire.com
FAQ
What is the new expiry date for Theralase (TLTFF) warrants issued in November 2022?
What is the exercise price of Theralase (TLTFF) warrants being extended?
How many warrants are affected by Theralase's (TLTFF) warrant extension?
